The synthesis and biological evaluation as antiviral agents of a series of racemic 4-aryl-1,2,3-triazolyl carbanucleosides of type (±)-10/(±)-11 related to the broad spectrum antiviral agent ribavirin 1 are described. These compounds were produced using a "click chemistry" strategy starting from readily available protected alcohol 13b. The synthetic approach made use of olefinbased organic reactions for the stereoselective construction of the appropriately functionalized cyclopentane ring moiety followed by copper (I) catalyzed Huisgen 1,3-dipolar cycloaddition of azides and alkynes for the regioselective construction of the heterocyclic triazole moiety.
Introduction
Ribavirin (Virazole ® , 1, Figure 1) 1 is a broad spectrum antiviral in clinical use for the treatment of RSV infections, lassa fever, hepatitis (A, B, and C), measles and mumps. The structure of this nucleoside analogue consists in a β-D-ribose ring attached to a 1,2,4-triazole derivative replacing the classic purine or pyrimidine base as the aglycon. Other nucleoside analogues owning 5-membered heterocyclic bases, such as imidazoles and triazoles, have displayed interesting biological properties; for instance, brenedin (Mizoribine as an immunosuppressor for the treatment of transplant patients 2 and EICAR (3, Figure 1 ), causes depletion of purine nucleotides resulting in a broad spectrum of activity against RNA and DNA viruses and tumour cell proliferation. 3 In this context, a great number 1,2,3-triazole derivatives have shown a great potential as antiviral, antibacterial or antiproliferative agents, 4 Furthermore, we and others have recently reported several examples of 1,2,3-triazolyl carbanucleosides owning promising biological activities ( Figure 2 ). 7 For example, compound (±)-6 (R = 2-C 6 H 4 OMe) exhibited specific inhibitory potential against TK + VZV (EC 50 = 11 μM), 8 7 was found to own moderate activity against HIV-1 (IC 50 = 43.8 μM), 9 and 8 In recent times we have started a research program devoted to the synthesis and biological evaluation as antiviral and antitumoral agents of carbanucleosides produced using, in some extent, the postulates of "click chemistry". In our previous work, 8 we reported on a series of racemic 4-aryl-1,2,3-triazolyl 2',3'-dideoxy-2'-iodocarbanucleosides of type (±)-6 ( Figure 2 ) and 4-aryl-1,2,3-triazolyl 2',3'-dideoxy-2',3'-didehydrocarbanucleosides of type (±)-9 ( Figure 3 ). These triazolyl carbanucleosides, structurally related to ribavirin 1, were produced using a iodoazidation reaction as the key step for the stereoselective construction of the desired functionalized cyclopentane ring, followed by the regioselective assembly of the heterocyclic moiety by a Cu(I) catalysed Huisgen 1,3-dipolar cycloaddition.
11
We present here our advances on the topic, reporting the synthesis and biological evaluation as antiviral agents of a series of 4-aryl-1,2,3-triazolyl 3'-deoxycarbanucleosides, of type (±)-10 and (±)-11 ( Figure 3 ). These compounds were designed to explore the effect on the antiviral activities of a different pattern of substitution at position 2' of the carbocycle, as well as the modification of the relative stereochemical configuration of the base with regard to the hydroxymethyl group at position 4' of the pseudosugar. 
Results and Discussion
Even when the number of references related to the "click chemistry" topic is increasing exponentially since the seminal review by Kolb Taking this considerations into account, we felt that our strategy for the rapid synthesis of carbanucleoside derivatives could not be only restricted to the use of the Huisgen cycloaddition for the construction of the heterocyclic base. For this reason, the designed strategy (Scheme 1) for the synthesis of our target compounds was intended to use olefin-based reactions as the key steps for the synthesis of the corresponding pseudosugar scaffold. As shown in Scheme 1, the synthesis of target compounds (±)-10/(±)-11 could be tackled by epoxidation of readily available protected derivatives of cyclopent-3-enylmethanol of general structure 13, leading to a mixture of epimers 14 that, upon nucleophilic ring opening of the oxirane ring, would lead to a mixture of stereoisomers (±)-15. Construction of the heterocyclic base using Cu(I) catalysed Huisgen 1,3-dipolar cycloaddition, 11 and further deprotection of the corresponding hydroxymethyl group, would lead to the target compounds. This synthetic plan would enable us to prepare several racemic 1,2,3-triazolocarbanucleoside derivatives differing in the relative stereochemical configuration of the functional groups attached to positions 1', 2' and 4' in the cyclopentane ring, with derivatives of type (±)-10 having a cis relationship between the base and the hydroxymethyl group at position 4' (the same relative configuration of natural nucleosides), and derivatives of type (±)-11, having a trans relationship between the above mentioned substituents. Starting from readily available known alkenes 13a 15 and 13b 8 (Scheme 2), epoxidation of 13a using MCPBA led, after purification by flash column chromatography, to a mixture of cis/trans epimers 14a/b in a 1:8 ratio as previously reported, 14, 15 with an improved yield of 91% (69% in the original paper). 15 The reaction of 13b with MCPBA produced, after chromatographic purification, an 81% yield of a mixture of cis/trans epimers 14c/d in a 1:3.8 ratio (by 1 H-NMR). 16 In both cases, attempts of separation of the mixtures were unsuccessful, leading only to partial resolution of epimers after successive flash column cromatographies. Concerning the nucleophilic ring opening of the resulting epoxides 14a/b and 14c/d, we selected the reaction conditions developed by Crotti et al, 17 that produced mixtures of racemic monoprotected azidoalcohols (±)-15a/b in a 86% yield and (±)-15c/d in a 94% yield (Scheme 2). Resolution of those by flash column chromatography was much easier than for the mixtures of epimeric epoxides 14a/b and 14c/d (see experimental section), so the needed separation of the corresponding isomers was performed at this stage of the synthetic route.
Since we wished to evaluate the effect on the biological activities of the relative configuration of the base and the hydroxymethyl group on position 4' of the cyclopentane ring of target compounds (±)-10/(±)-11, we consequently decided to follow the synthetic plan using the TBDPS diastereomeric precursors ((±)-15c/d), as they could be produced in more equitable quantities than their TBDMS ((±)-15a/b) counterparts.
Construction of the desired 4-aryl-1,2,3-triazole moiety was achieved (Scheme 3 and Table  1 ) using Cu(I) catalysed Huisgen's 1,3-dipolar cycloaddition. 11, 18 As expected, this methodology produced only one of the two possible regioisomers ((±)-16a-c/(±)-17a-c). Using large amounts of DIPEA and excess CuI (Method B) the reaction yielded the corresponding 1,2,3-triazole derivatives with good yields (entries 2, 5-7; Table 1 ). On the contrary, differing from our previous results, 8 only moderate yields of the desired products (±)-16a-c (entries 1, 3, 4; Table 1) were obtained using 2 equivalents of the base and a catalytic amount of CuI (Method A). In addition, in most of the cases (entries 1-6, Table 1 ), a small amount of the corresponding triazole iodinated at position 5 of the heterocycle was isolated ((±)-18a-c/(±)-19a-b). 19 Deprotection of the silyl protecting group using TBAF generated the target compounds (±)-10a-c/(±)-11a-c in good yields (74-99%). Table 1 for details) and deprotection of the TBDPS protecting group leading to target compounds (±)-10a-c/(±)-11a-c. 
Method A: DIPEA (2 eq.), CuI (0.05-0.1 eq). Method B: DIPEA (50 eq.), CuI (1-2 eq.). b Isolated yields after flash column chromatography. In all the cases, these 1,2,3-triazolocarbanucleosides did not show any specific antiviral effects (i.e. minimal antiviral effective concentration ≤ 5-fold lower than the minimal cytotoxic concentration for the host cell) against any of the viruses in the assay systems used.
More promising results were obtained in the antiviral evaluation of the silylated derivatives 
Experimental Section
General Procedures. All chemicals used were of reagent grade, obtained from Aldrich Chemical Co. and used without further purification. Starting materials 13a/b were prepared following previously reported methods. 8, 15 Melting points were measured in a Reichert Kofler Epoxidation of tert-butyldimethylsilyl (cyclopent-3-enyl)methyl ether (13a) and tertbutyldiphenylsilyl (cyclopent-3-enyl)methyl ether (13b). A solution of the corresponding alkene 13a 15 or 13b 8 (1 mmol) in dry CH 2 Cl 2 (5 mL) was slowly added to a well stirred suspension of MCPBA (1.2 mmol) in dry CH 2 Cl 2 (5 mL). The reaction mixture was then heated at reflux until complete disappearance of the starting material was detected by TLC. The solution was then cooled to 0ºC, the solid in suspension filtered and washed with a small amount of cold CH 2 Cl 2 . The filtrate was washed with a 10% aqueous solution of Na 2 SO 3 (10 mL), a 10% aqueous solution of NaHCO 3 (10 mL) and brine (10 mL). The organic layer was dried (Na 2 SO 4 ) and the solvent concentrated under reduced pressure. The corresponding residue was purified by flash column chromatography (see below for further details). cis-tert-Butyldimethylsilyl (3,4-epoxycyclopentyl)methyl ether 14a and trans-tertbutyldimethylsilyl (3,4-epoxycyclopentyl)methyl ether (14b). A first flash column chromatography of the crude reaction product using CH 2 Cl 2 as eluent afforded the pure mixture of the epoxides 14a/b in a 91% yield, an increase of a 24% in the previously reported yield. 14, 15 A second column chromatography using hexane-CH 2 Cl 2 1:1 as eluent afforded successively 14a (9%), 14a+14b (60%) and 14b (31%). The physical data for 14a/b were coincident with those reported in the bibliography. Once the reaction was complete, the mixture was cooled to room temperature, diluted with water 50 mL and extracted with ether (3 x 25 mL). The organic layer was dried (Na 2 SO 4 ) and the solvents evaporated under reduced pressure yielding an oily residue that was purified by flash column chromatography (see below for further details).
(±)-t-2-Azido-c-4-(tert-butyldimethylsilyloxymethyl)cyclopentan-r-1-ol ((±)-15a) and (±)-t-2-azido-t-4-(tert-butyldimethylsilyloxymethyl)cyclopentan-r-1-ol ((±)-15b).
The crude mixture of isomers (obtained in 86% yield) was subjected to column chromatography on silica gel using hexane-EtOAc 15:1 as eluent to give, successively, (±)-15a (24%) in a first group of fractions and a mixture of (±)-15a/b (10%) in a second group. A third group of fractions, eluted with hexane-EtOAc 10:1, afforded (±)-15b (66%). Table 1 .The reactions were monitored by TLC until the complete disappearance of the starting material. The yellow solid in suspension was then filtered, the solvents were removed under reduced pressure, and resulting residue was dissolved in EtOAc and washed with water. The organic layer was dried (Na 2 SO 4 ) and the solvent removed under reduced pressure. The obtained residue was purified by column chromatography on silica gel (see below for further details).
(±)-t-2-Azido-c-4-(tert-butyldiphenylsilyloxymethyl)cyclopentan-r-1-ol ((±)-15c) and (±)-t-2-azido-t-4-(tert-butyldiphenylsilyloxymethyl)cyclopentan-r-1-ol ((±)-15d

Method B.
A suspension of the corresponding monoprotected azidodiol (±)-15c/d (1 mmol), aryl alkyne (2 mmol), CuI (1-2 mmol) and DIPEA (50 mmol) in dry THF (50 mL) was stirred under the conditions specified in Table 1 . The reactions were monitored by TLC and the work-up carried out in the same manner as for Method A. 1H-1,2,3-triazol-1-yl)-r-1-cyclopentanol ((±)-18a) . Method A. The non-void fractions eluted successively with hexane-EtOAc 7:1 and 4:1 afforded successively (±)-18a (13%) and (±)-16a (30%). Method B. The non-void fractions eluting with hexane-EtOAc 7:1 and 4:1 afforded (±)-18a (3%) and (±)-16a (72%) as a white solid that presented identical spectroscopic features to that using Method A. 
(±)-c-4-(tert-Butyldiphenylsilyloxymethyl)-t-2-(4-phenyl-1H-1,2,3-triazol-1-yl)-r-1-cyclopentanol ((±)-16a) and (±)-c-4-(tert-butyldiphenylsilyloxymethyl)-t-2-(4-phenyl -5-iodo-
